| Regulatory Compliance | Marketing authorization | The injectable presentation must be legally authorized in the destination market. The approved strength, dosage form, route of administration, storage conditions, and reconstitution instructions must match the supplied product. | Current marketing authorization, approved product information, manufacturing-site details, and authorization status applicable to the importing country. | Products without a valid local pathway may create import delays, relabeling costs, or regulatory rejection. |
| Regulatory Compliance | Good Manufacturing Practice | The finished-product and active-pharmaceutical-ingredient facilities should operate under an applicable GMP system, with sterile manufacturing controls appropriate for parenteral products. | Current GMP certificate or inspection evidence, manufacturing-site authorization, recent inspection history, and a description of critical deficiencies and corrective actions. | A lower unit price is not advantageous if the supplier has unresolved inspection findings or cannot support import clearance. |
| Regulatory Compliance | Technical dossier completeness | The dossier should cover the active ingredient, finished-product formulation, manufacturing process, process controls, validation, specifications, stability, packaging, and clinical or safety information required by the destination authority. | Relevant CTD sections, product specification, validation summaries, stability protocol, batch records or representative manufacturing documents, and change-control history. | Incomplete documentation increases qualification time and may require regulatory consulting or additional testing. |
| Regulatory Compliance | Pharmacopoeial alignment | Testing should follow the applicable monograph or an approved in-house specification. Common reference frameworks include the current pharmacopoeia recognized by the destination authority and internationally accepted GMP guidance. | Current analytical methods, method-validation or verification reports, reference-standard qualification, and a cross-reference between the release specification and the applicable monograph. | Different pharmacopoeial requirements can change testing costs, release timelines, and batch comparability. |
| Product Quality | Active ingredient identity | The active ingredient should be identified as amoxicillin sodium and should meet the approved chemical, optical, purity, and potency requirements. The sodium-salt form must be clearly defined in the specification. | Certificate of analysis, identity-test results, active-ingredient specification, supplier qualification records, and confirmation of the salt form and grade used. | Substitution with a different salt or non-equivalent grade can invalidate the product specification and registration. |
| Product Quality | Strength and presentation | Common injectable presentations may include 500 mg and 1 g strengths, but only the strength and container configuration authorized for the destination market should be sourced. | Approved label, vial or ampoule specification, fill quantity, overfill justification where applicable, and finished-product assay results from representative batches. | Larger vial sizes may reduce packaging cost per gram but can increase wastage if the clinical demand is low. |
| Product Quality | Sterility assurance | The finished product must comply with the applicable sterility test and be manufactured using a validated sterile process. A passing sterility test alone does not replace process validation and contamination-control evidence. | Sterility-test results, aseptic-process simulation records, sterilization or sterile-filtration validation, environmental-monitoring trends, and media-fill deviation records. | Weak sterility assurance creates high recall, shortage, and patient-safety exposure regardless of purchase price. |
| Product Quality | Bacterial endotoxins | The product must meet the applicable bacterial-endotoxin limit calculated for the intended parenteral route and maximum dose. The limit should be justified in the approved specification. | Endotoxin method, validation or suitability data, batch results, alert/action limits, and investigation records for atypical results. | Additional endotoxin controls may increase testing cost but materially reduce the risk of failed release or clinical use. |
| Product Quality | Visible and subvisible particulates | The reconstituted injection should comply with applicable requirements for visible and subvisible particulate matter, such as those described in recognized injectable-product standards. | Particulate-test results, container-closure inspection data, visual-inspection qualification, defect classification, and trend reports. | High particulate-failure rates can cause batch rejection, repackaging expense, and supply interruption. |
| Product Quality | Related substances and degradation | Impurity and degradation-product levels must remain within the approved specification throughout shelf life. Beta-lactam degradation should be specifically controlled through validated stability-indicating methods. | Chromatograms, related-substance profile, assay and degradation data, analytical-method validation, and out-of-specification investigation history. | A weak impurity profile may shorten shelf life and increase inventory write-offs. |
| Product Quality | Container-closure integrity | The vial, stopper, seal, and packaging system must protect the sterile powder from moisture, oxygen, light, and microbial ingress for the full approved shelf life. | Container-closure integrity validation, extractables and leachables assessment where applicable, packaging specifications, and transport-simulation results. | A more protective package may cost more but can reduce stability failures and temperature-related claims. |
| Product Quality | Stability and shelf life | Shelf life should be supported by long-term and accelerated stability data under the labeled storage conditions. ICH Q1A principles are commonly used where accepted by the authority. | Stability protocol, at least three representative batches where applicable, long-term data, accelerated data, photostability data where relevant, and post-reconstitution stability instructions. | A longer validated shelf life can reduce expiry losses and safety-stock requirements. |
| Product Quality | Reconstitution performance | The product should have clear instructions for diluent, volume, concentration, dissolution time, in-use period, and storage after reconstitution. These instructions must be supported by compatibility and stability data. | Reconstitution study, in-use stability data, compatibility data with permitted diluents, visual-appearance assessment, and instructions for handling unused solution. | Poor reconstitution performance can increase administration time, wastage, and nursing workload. |
| Supply Reliability | Batch consistency | The supplier should demonstrate consistent assay, impurity, endotoxin, sterility, particulate, and fill-volume performance across recent commercial-scale batches. | At least three recent batch certificates of analysis, annual product-quality review, deviation summary, complaint trend, and recall history. | Consistent batches support predictable release and reduce the need for incoming quarantine testing. |
| Supply Reliability | Manufacturing capacity | Capacity should be evaluated against annual demand, minimum order quantity, campaign schedule, lead time, and planned maintenance. Sterile products require particular attention to filling-line availability. | Capacity statement, production calendar, lead-time commitment, minimum order quantity, allocation policy, and business-continuity plan. | A low price with constrained capacity can result in emergency purchases at a much higher total cost. |
| Pricing | Price normalization | Compare offers on the same basis: strength, vial count, active amount, pack configuration, Incoterm, payment terms, remaining shelf life, testing included, freight, insurance, duties, and local release costs. | Formal quotation with currency, Incoterm, validity period, price per vial and per gram of amoxicillin equivalent, packaging details, and all excluded charges. | The lowest quoted ex-works price may not be the lowest landed or usable cost. |
| Pricing | Total landed cost | Use: total landed cost = product price + freight + insurance + duties/taxes + import fees + testing + local release + cold-chain or special handling + expected wastage. | Freight quotation, customs classification, duty estimate, testing quotation, local-release fee schedule, and wastage assumption. | A transparent landed-cost model allows objective comparison between domestic and international supply options. |
| Pricing | Price validity and escalation | For 2026 contracts, define quotation validity, raw-material adjustment rules, currency treatment, freight-sur surcharge rules, and the maximum annual price-escalation mechanism. | Draft supply agreement, price-adjustment formula, currency clause, force-majeure clause, and notice period for changes. | Undefined escalation terms can eliminate savings during a multi-year supply agreement. |
| Pricing | Quality-related charges | Confirm whether release testing, additional pharmacopoeial testing, sample dispatch, dossier review, audit support, stability monitoring, and deviation investigations are included in the quoted price. | Charge schedule, quality agreement, testing responsibility matrix, and change-control fee policy. | Hidden quality charges can materially change the comparison between suppliers. |
| Logistics | Storage and transport conditions | Follow the approved label and stability data for temperature, humidity, light protection, and handling. Do not assume that all presentations require the same transport conditions. | Label storage statement, transport qualification, packaging validation, temperature-monitoring plan, and excursion-management procedure. | Incorrect storage can cause rejected shipments, stability claims, and product loss. |
| Logistics | Remaining shelf life at delivery | Set a contractual minimum remaining shelf life, such as a defined percentage of total shelf life or a defined number of months, according to demand and local release time. | Batch release date, expiry date, forecasted dispatch date, and contractual shelf-life guarantee. | Short-dated inventory increases expiry risk and may require a discounted price or replacement commitment. |
| Supplier Qualification | Quality agreement | The agreement should assign responsibilities for deviations, complaints, recalls, change notification, audits, batch release, record retention, data integrity, and regulatory communication. | Executed or reviewable quality agreement, change-control procedure, recall procedure, complaint procedure, and contact escalation list. | Clear responsibilities reduce dispute risk and accelerate corrective action. |
| Supplier Qualification | Data integrity | Electronic and paper records should be attributable, legible, contemporaneous, original, accurate, complete, consistent, enduring, and available, consistent with recognized data-integrity expectations. | Data-integrity policy, audit-trail controls, laboratory-system validation summary, record-retention policy, and recent audit observations. | Data-integrity weaknesses may result in regulatory non-acceptance and costly requalification. |
| Supplier Qualification | Final supplier score | Use a weighted scorecard: regulatory compliance 30%, product quality 30%, supply reliability 20%, total landed cost 15%, and service/communication 5%. Set a minimum pass score and mandatory fail criteria. | Completed scorecard, approved deviations, risk assessment, audit report, and documented management approval. | A weighted model prevents price from dominating critical sterile-product decisions. |
